0001179110-18-013103.txt : 20181121
0001179110-18-013103.hdr.sgml : 20181121
20181121171921
ACCESSION NUMBER: 0001179110-18-013103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181119
FILED AS OF DATE: 20181121
DATE AS OF CHANGE: 20181121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wicki Andreas
CENTRAL INDEX KEY: 0001511472
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 181198832
MAIL ADDRESS:
STREET 1: C/O HBM BIOVENTURES (CAYMAN) LTD.
STREET 2: CENTENNIAL TOWERS,STE.305,2454 W.BAY RD.
CITY: GRAND CAYMAN
STATE: E9
ZIP: E9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
edgar.xml
FORM 4 -
X0306
4
2018-11-19
0
0001396814
Pacira Pharmaceuticals, Inc.
PCRX
0001511472
Wicki Andreas
GOVERNORS SQUARE, SUITE 4-212-2,
23 LIME TREE BAY AVE. WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
1
0
0
0
Common Stock
2018-11-19
4
S
0
990
47.0761
D
964889
I
See footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.03 to $47.25 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Mehdi Khodadad (Attorney-in-Fact)
2018-11-20